NYNRIN and neoplasm: At the time of diagnosis, the tumor cells had four distinct SNVs in USP54, GABRA3, KRAS and SETD2, while the relapsed tumor acquired four additional unique mutations in MYH7, NYNRIN, ODZ1 and ZIC3 (Figure 3A).